-
公开(公告)号：US20240342230A1
公开(公告)日：2024-10-17
申请号：US18427221
申请日：2024-01-30
申请人： FERRING B.V. , INSTITUT PASTEUR
发明人： Pascal Danglas , Laurent Debarbieux
CPC分类号： A61K35/76 , A61K9/0053 , C12N7/00 , C12N2795/10021 , C12N2795/10132 , C12N2795/10171 , Y02A50/30
摘要： The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject.
The subject invention also provides new bacteriophage strains.-
公开(公告)号：US20240287468A1
公开(公告)日：2024-08-29
申请号：US18570436
申请日：2022-06-14
申请人： Ferring B.V.
IPC分类号： C12N7/00 , A61K35/741 , A61K35/76 , A61K36/064 , A61K39/00 , A61K39/09 , A61P31/04
CPC分类号： C12N7/00 , A61K35/741 , A61K35/76 , A61K36/064 , A61K39/09 , A61P31/04 , A61K2039/521 , C12N2795/00021 , C12N2795/00032
摘要： Described herein are bacteriophages that infect and lyse Vancomycin-Resistant Enterococci (VRE). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with Enterococci, including VRE, or who are at risk of infection by Enterococci, including VRE, and for other uses described herein.
-
公开(公告)号：US20230372447A1
公开(公告)日：2023-11-23
申请号：US18138000
申请日：2023-04-21
申请人： Ferring B.V.
CPC分类号： A61K38/24 , A61K9/0019 , A61K47/183 , A61K9/08 , A61P15/08 , A61K47/26 , A61K47/10
摘要： The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.
-
公开(公告)号：US20230357322A1
公开(公告)日：2023-11-09
申请号：US18142470
申请日：2023-05-02
申请人： Ferring B.V.
发明人： Elizabeth Serrano CHAVEZ , Helen SJOEGREN , Jette BOLL , Hayley REECE , Jonathan James LOUGHREY
IPC分类号： C07K7/16
CPC分类号： C07K7/16 , C07B2200/13
摘要： The present invention relates to crystalline forms of carbetocin, a method of their manufacture, and pharmaceutical compositions thereof.
-
公开(公告)号：US20230346704A1
公开(公告)日：2023-11-02
申请号：US18128922
申请日：2023-03-30
申请人： Ferring B.V.
IPC分类号： A61K9/16 , A61K31/4545 , A61K31/519 , A61K9/19 , A61K31/4725
CPC分类号： A61K9/1623 , A61K9/1664 , A61K9/1682 , A61K9/19 , A61K31/4545 , A61K31/4725 , A61K31/519
摘要： A free-flowing solid pharmaceutical formulation comprising one or more active ingredients and a blend comprising sorbitol and liquid paraffin, a package containing the formulation, a process for the manufacture of the formulation and the use of the blend in the formulation.
-
公开(公告)号：US11752157B2
公开(公告)日：2023-09-12
申请号：US16877186
申请日：2020-05-18
申请人： Ferring B.V.
发明人： Joan-Carles Arce
IPC分类号： A61K31/404 , A61B17/435 , A61K31/57 , A61K38/095 , A61K38/12 , A61K45/06 , A61K31/4045 , A61K31/565 , A61K9/00
CPC分类号： A61K31/57 , A61B17/435 , A61K9/0019 , A61K9/0034 , A61K31/404 , A61K31/4045 , A61K31/565 , A61K38/095 , A61K38/12 , A61K45/06 , A61K31/4045 , A61K2300/00 , A61K31/57 , A61K2300/00 , A61K31/565 , A61K2300/00
摘要： The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.
-
公开(公告)号：US11712422B2
公开(公告)日：2023-08-01
申请号：US17117599
申请日：2020-12-10
申请人： FERRING B.V.
发明人： Soren Halskov
CPC分类号： A61K9/5073 , A61K9/0095 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K33/44 , A61K9/2081
摘要： The invention provides a pharmaceutical composition comprising activated carbon particles, for oral administration. The pharmaceutical composition may be for (use in) the treatment of gastrointestinal fistula.
-
公开(公告)号：US20230210955A1
公开(公告)日：2023-07-06
申请号：US17928176
申请日：2021-05-28
申请人： FERRING B.V.
发明人： Patrick HEISER , Eric FOSTER
IPC分类号： A61K38/24 , A61B17/435 , A61P15/08
CPC分类号： A61K38/24 , A61B17/435 , A61P15/08
摘要： The present invention relates to improved assisted reproductive technology for women predicted to have a high ovarian response to controlled ovarian stimulation that comprise targeting a threshold serum hCG level by the final day of stimulation.
-
公开(公告)号：US11666635B2
公开(公告)日：2023-06-06
申请号：US17020279
申请日：2020-09-14
申请人： Ferring B.V.
CPC分类号： A61K38/24 , A61K9/0019 , A61K9/08 , A61K47/10 , A61K47/183 , A61K47/26 , A61P15/08
摘要： The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.
-
公开(公告)号：US20230139407A1
公开(公告)日：2023-05-04
申请号：US17817274
申请日：2022-08-03
申请人： Ferring B.V.
摘要： Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
-
-
-
-
-
-
-
-
-
搜索结果
230 条记录 (耗时 0.027 秒)
